Jupiter Neurosciences has initiated a Phase 2a trial of JOTROL, a trans-resveratrol formulation engineered for central nervous system penetration, in 30 Parkinson's disease patients. Phase 1 data demonstrated ninefold higher bioavailability and measurable cerebrospinal fluid levels without serious adverse events, establishing a foundation for evaluating safety and efficacy in symptomatic populations.
Key Points
- Phase 1 showed ninefold higher plasma bioavailability than conventional resveratrol
- Measurable CSF drug levels confirm blood-brain barrier penetration
- 12-week Phase 2a trial enrolling 30 patients across three dose groups
Longevity Analysis
Parkinson's disease progression involves mitochondrial dysfunction, neuroinflammation, and protein aggregation—processes that resveratrol addresses through multiple mechanisms. The critical barrier in previous resveratrol research has been achieving therapeutic concentration in neural tissue; this formulation's demonstrated CNS penetration may enable the polyphenol to modulate energy production and defend against oxidative stress at the site of neurodegeneration. Secondary endpoints measuring ATP levels and inflammatory markers will clarify whether improved bioavailability translates to measurable systemic benefit, providing empirical evidence for whether bioavailability gains result in clinically meaningful outcomes.
Original published by LT Wire.